The Effect of Mindfulness on Vascular Inflammation in Stable Coronary Disease

Description

This study aims to evaluate the effect of 8 weeks of a stress reduction intervention on atherosclerotic plaque inflammation in adults with stable coronary artery disease, as quantified by positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in individuals with increased psychosocial stress.

Conditions

Atherosclerosis, Stress, Inflammation

Talk to us

Study Overview

On this page

Study Details

Study overview

This study aims to evaluate the effect of 8 weeks of a stress reduction intervention on atherosclerotic plaque inflammation in adults with stable coronary artery disease, as quantified by positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in individuals with increased psychosocial stress.

The Effect of Mindfulness on Vascular Inflammation in Stable Coronary Disease: A Multi-System PET/MRI Study

The Effect of Mindfulness on Vascular Inflammation in Stable Coronary Disease

Condition
Atherosclerosis
Intervention / Treatment

-

Contacts and Locations

Boston

Massachusetts General Hospital, Boston, Massachusetts, United States, 02114

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Must admit to feeling stressed and/or have PSS score \> 13 (moderate stress)
  • * Must be willing to complete stress reduction course and imaging sessions with \< 3 missed appointments in last year
  • * Known clinical cardiovascular disease with prior atherosclerotic myocardial infarction, percutaneous intervention or bypass surgery \> 6 months before entry, or severe coronary calcifications on computed tomography or coronary calcium score \>400
  • * Stable symptoms without symptomatic heart failure or arrhythmia or planned revascularization
  • * Maximally tolerated and stable medical regimen for 90 days that does not include a high intensity statin for clinical reasons
  • * No neurological disease or systemic inflammatory disease/current anti-inflammatory therapy
  • * No active psychiatric disease/medications or substance abuse (including tobacco smoking or more than moderate alcohol) for last 6 months
  • * No current participation in cardiac rehab or prior participation in stress reduction
  • * For imaging: no pregnancy, weight \> 300 lbs., metal implants, uncontrolled hyperglycemia, or inability to provide consent or comply

Ages Eligible for Study

45 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Massachusetts General Hospital,

Michael T Osborne, MD, PRINCIPAL_INVESTIGATOR, Massachusetts General Hospital

Study Record Dates

2026-10